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Abstract Rotavirus Efficacy and Safety Trial (REST) en-
rolled nearly 70,000 infants, of whom more than 23,000
were from Finland. REST determined the efficacy of the
pentavalent rotavirus vaccine (RV5) against rotavirus-related
hospitalisations and emergency department (ED) visits in the
first year after vaccination. Finnish infants initially in REST
transitioned into the Finnish Extension Study (FES), where
they were followed for rotavirus-related hospitalisations and
ED visits through their second year of life and beyond. FES
identified 150 (31%) additional rotavirus gastroenteritis
(RVGE) cases beyond those identified in REST in the
Finnish participants. Overall, RV5 reduced RVGE hospital-
isations and ED visits, regardless of the rotavirus serotype,
by 93.8% (95% confidence interval [CI]: 90.8–95.9%) for up
to 3.1 years following the last vaccine dose. Vaccine efficacy
against combined hospitalisations and ED visits between
ages 4 months to 11 months, 12 months to 23 months, and
24 months to 35 months was 93.9% (95% CI: 89.1–96.9%),
94.4% (95% CI: 90.2–97.0%), and 85.9% (95% CI: 51.6–
97.2%), respectively. The reduction of hospitalisations and
ED visits due to any acute gastroenteritis, rotavirus or not,
was 62.4% (95% CI: 57.6–66.6%) over the entire follow-up
period. The results from FES confirm that RV5 induces high
and sustained protection against rotavirus-related hospital-
isations and ED visits, and has a very substantial impact on
all gastroenteritis-related hospitalisations and ED visits into
the third year of life in Finnish children.
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Introduction
Finland has a heavy burden of rotavirus disease. Prior to
the introduction of rotavirus vaccination in Finland, one
child in 33 was hospitalised for rotavirus gastroenteritis
(RVGE) [17], which is one of the highest hospitalisation
rates in Europe (Pediatric ROTavirus European Commit-
Tee [PROTECT]) [8]. Finland also has a long and distinct
rotavirus epidemic season, which starts as early as Novem-
ber or December and lasts until June or July [17]. Over the
years, numerous clinical trials evaluating candidate rotavi-
rus vaccines were conducted in Finland [4, 13, 16], and
Finland contributed significantly to the Rotavirus Efficacy
and Safety Trial (REST), evaluating the pentavalent rota-
virus vaccine (RV5), RotaTeq® (Merck & Co., Whitehouse
Station, NJ, USA). In REST, Finland enrolled more than
23,000 of the approximately 70,000 infants, and contribut-
ed more than one-half of the cases of rotavirus gastroen-
teritis in the efficacy analysis [15].
In REST, all infants in the large-scale safety study were
followed for hospitalisations and emergency department
(ED) visits for 365 days after their first vaccination, when
children were from 13.5 months to 15 months old, and a
subset (clinical-efficacy substudy) was followed for epi-
sodes of RVGE for up to 2 years. In Finland, and in Europe
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second year of life, when infants usually attend day-care
centres [10]. We have recently shown that among the
Finnish infants in the clinical-efficacy cohort of REST, the
efficacy of RV5 was 98.3% against severe RVGE and
68.0% against RVGE of any severity, during the first and
second rotavirus seasons combined [19]. Additionally, in
this cohort, there was a statistically significant shift in the
types of health care encounters towards less intensive care
settings among vaccine recipients compared to the placebo
recipients for the first 2 years following vaccination.Using
the large-scale safety cohort of more than 23,000 Finnish
infants, the Finnish Extension Study (FES) was carried out
to supplement the follow-up period of REST and demon-
strate the potential full impact of RV5. In the United States,
the majority of RVGE health care encounters occur in the
first year of life; thus, continued follow-up after REST was
not necessary. In FES, Finnish infants in the large-scale
safety study who were followed for 365 days after the first
vaccination visit immediately transitioned from REST into
FES, where they were followed for episodes of RVGE that
required hospitalisation or an ED visit from their second
year of life. Here, we present the results of the combined
efficacy follow-up of RV5 in the Finnish participants of
REST and FES up to 3.1 years of age.
Rotavirus vaccination has been incorporated into the na-
tional immunisation programme in Finland since September
2009 [6], based on estimates of high burden of disease and
cost-effectiveness of vaccination [3]. RV5 vaccine was
chosen for the vaccination programme in Finland [6]. The
findings of FES highlight the expected benefits from a
universal rotavirus vaccination programme in Finland.
Materials and methods
Study design
The methods used in FES generally conformed to the
original REST protocol, the details of which have been
published [15]. In brief, REST was a double-blind, placebo-
controlled, randomised trial of nearly 70,000 infants.
Healthy infants between 6 weeks and 12 weeks of age
were eligible for the study. Infants were randomised 1:1 to
receive three doses of either RV5 or placebo. REST
evaluated the large-scale safety of RV5, primarily with
respect to intussusception. The efficacy of RV5 was
evaluated mainly for reduction in hospitalisations and ED
visits because of acute gastroenteritis (AGE). The efficacy
follow-up in the safety cohort lasted for 365 days. In
addition, in a subset of infants in Finland and the United
States, efficacy was evaluated for all AGE; this follow-up
lasted, in some subjects, up to 2 years.
In Finland, infants received RV5 vaccine or placebo at 2,
3, and 4 to 5 months of age. Infants were enrolled from 30
sites located throughout the country. A total of 23,422
Finnish infants were enrolled in REST between 2 February
2001 and 13 August 2003, 2,271 in the clinical efficacy
subset and 21,151 in the large-scale safety study that
followed infants for RVGE-associated hospitalisations and
ED visits for 365 days after the first dose. All the Finnish
infants originally enrolled in REST were invited to continue
on into FES, with the exception of the 2,271 Finnish infants
in the clinical-efficacy substudy. Because the clinical-
efficacy cohort did not transition into FES, the severity of
rotavirus disease was not determined. The majority (20,732)
of the Finnish infants in the large-scale safety study
transitioned from REST into FES after they had completed
the final 365-day contact in REST, or when they had reached
either the study site’s prespecified end date or the Finland
end-of-study date in REST (31 December 2003), whichever
date was earlier. In FES, infants were followed for hospital-
isations and ED visits for RVGE or intussusception until 31
May 2004. FES captured additional health care encounters
that occurred after the termination of REST in year 1 and
year 2 post-vaccination, and allowed for the collection of
health care encounters in year 3 post-vaccination. The FES
protocol was approved by the Sub-Committee on Medical
Research Ethics (TUKIJA) of the National Ethics Committee
in Finland, and written informed consent was obtained from
the parents of children who continued in FES.
Monitoring for health care encounters in FES followed
the same approach that was used to monitor infants in
REST [15]. However, in FES, episodes of AGE requiring
hospitalisation or an ED visit were collected at prespecified
12-week intervals by automated short message service
contacts, sent via mobile phones, or by direct telephone
calls for those without access to text messaging, rather than
at 6-week intervals as in REST [15, 18]. Case report forms
in FES were modelled after the case report forms in REST
[15, 18].
Efficacy analysis
For consistency, the case definition of RVGE and the assays
used to detect and type rotavirus in the stool samples
collected in FES were the same as in REST [15]. RVGE was
defined as forceful vomiting and/or three or more watery or
looser-than-normal stools within a 24-hour period, along
with the detection of rotavirus by enzyme immunoassay [21]
in a stool specimen obtained within 14 days after symptom
onset. Reverse transcription-polymerase chain reaction
assays were used to determine the VP7 and VP4 genotypes
[1, 15].
Vaccine efficacy in preventing RVGE hospitalisations
and ED visits, regardless of rotavirus serotype, was
1380 Eur J Pediatr (2010) 169:1379–1386examined in the per-protocol and intention-to-treat popula-
tions as previously described [18]. The per-protocol
population included infants who received all three doses
of RV5 or placebo, and for whom there were no protocol
violations. The intention-to-treat population included
infants who received at least one dose of RV5 or placebo.
Measures of efficacy were assessed beginning 14 days after
the third dose in the per-protocol population and any time
immediately after the first dose in the intention-to-treat
population. Because of rolling enrollment in REST, the
duration of follow-up differed among subjects in REST and
FES. For this reason, rates of hospitalisations and ED visits
were expressed as the annual number of encounters per
1,000 person-years. Efficacy was calculated as previously
described [18].
Results
Study population
In Finland, the median age of entry in REST was 10 weeks.
A total of 21,151 infants were enrolled in the large-scale
safety study of REST, 20,732 (∼98%) of whom continued
in FES. The demographic characteristics of the Finnish
infants in the vaccine and placebo groups in the large-scale
safety study are shown in Table 1. In addition, 2,271 infants
were enrolled in the efficacy subset, with efficacy follow-up
for up to 2 years. In FES, subjects were followed for up to
3.1 years after the third vaccine dose, which is equivalent to
∼3.5 years of age. Depending on the date of entry in the
original REST study, which enrolled infants over a period
of 3 years in Finland, the number of children included in
the analysis for each year differed, with the duration of
follow-up in REST+FES greatest for those who were
enrolled early in REST. The mean duration of follow-up
in FES was 573 days (range, 29–1,126 days). The FES
added 18,655 person-years of follow-up and identified 31%
more cases than REST alone. The number of evaluable
subjects refers to that for the entire analysis.
Viral findings
During the FES, 270 samples fulfilling the criteria of gastro-
enteritis were collected, and 177 (66%) were rotavirus-
positive. Of the remaining samples, 254 were available for
studies of human caliciviruses, and 30 were positive. These
included 27 noroviruses and three sapoviruses; other
gastroenteritis viruses were not studied. The results of this
investigation will be published separately.
Vaccine efficacy in the per-protocol population
Among the Finnish infants in REST, there were a total of
17 RVGE-related hospitalisations and ED visits among
vaccine recipients and 310 among placebo recipients
providing an overall rate reduction of 94.5% (95% CI:
91.2–96.9). During the 3.1 years of follow-up time post
vaccination, RV5 significantly reduced the rate of hospital-
isations and ED visits for RVGE in Finland (Table 2).
Overall, in REST+FES, 21,941 subjects with 34,407 person-
years of follow-up time were followed for rotavirus-related
health care encounters. There were 28 health care encounters
among vaccine recipients and 449 among placebo recipients.
Among the vaccine recipients, 22 of the health care
encounters occurred in year 1, six occurred in year 2, and
there were none in year 3 of follow-up. None of the health
care encounters that occurred beyond the first year among
the vaccine recipients were the result of a recurrent episode.
Among the placebo recipients, 351 of the 449 health care
encounters occurred in year 1, 97 occurred in year 2, and
there was one in year 3. Overall, 39% of all RVGE
hospitalisations and ED visits in the vaccine group and
31% in the placebo group in REST+FES in Finland occurred
during the follow-up period of FES.
Overall, in REST+FES, vaccine efficacy at reducing
hospitalisations and ED visits combined in Finland was
93.8% (95% CI: 90.8–95.9%) for up to 3.1 years following
the last dose of vaccine. In the first year post vaccination,
vaccination with RV5 reduced the rate of hospitalisations
and ED combined by 93.7% (95% CI: 90.4–96.1%). In the
second year post vaccination, among the 16,189 evaluable
infants in REST+FES, the vaccine reduced the rate of
Table 1 Demographic characteristics of the infants enrolled in the
Finnish Extension Study
Variable RV5 Placebo
Children assigned to group, n 10,367 10,365
Gender, n (%)
Boys 5245 (50.6) 5229 (50.5)
Girls 5122 (49.4) 5136 (49.6)
Age at entry, weeks
Mean±SD 10.4±1.3 10.4±1.4
Median 11.0 11.0
Range 6–13 6–13
Race or ethnic group, n (%)
White 10,263 (99.0) 10,271 (99.1)
Hispanic 0 0
Black 5 (0.1) 0
Multiracial 94 (0.9) 89 (0.9)
Asian 5 (0.1) 5 (0.1)
Native American NA NA
Other 0 0
RV5 pentavalent rotavirus vaccine, NA not applicable
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1382 Eur J Pediatr (2010) 169:1379–1386hospitalisations and ED visits combined by 93.9% (95%
CI: 86.0–97.8%), with a 90.8% (95% CI: 76.9–97.1%)
reduction in hospitalisations, and a 97.7% (95% CI: 86.3–
99.9%) reduction in ED visits. In the third year post
vaccination, FES followed 6,032 evaluable subjects. During
this time, there was only one RVGE-related health care
encounter, an ED visit by a placebo recipient.
Vaccine efficacy in the intention-to-treat population
The intention-to-treat population included all infants who
received at least one dose of vaccine, and for whom health
care encounters were counted beginning immediately after
the administration of the first dose rather than 14 days after
the third dose (Table 2). Overall, during REST+FES, RV5
reduced the rate of hospitalisations and ED visits combined
by 92.3% (95% CI: 89.2–94.6%), with a 91.7% (95% CI:
86.6–95.0%) reduction in hospitalisations, and a 92.9% (95%
CI: 88.4–95.7%) reduction in ED visits in the intention-to-
treat population. In the first and second years post vacci-
nation, RV5 reduced the rate of combined hospitalisations
and ED visits by 92.0% (95% CI: 88.0–94.7%) and 92.7%
(95% CI: 86.4–96.4%), respectively. In the third year post
vaccination, vaccine efficacy against RVGE health care
encounters was 100% (95% CI: 29.7–100%), but there were
only seven encounters among 8,503 subjects in REST+FES,
all of which occurred in placebo recipients (Table 2).
Vaccine efficacy at reducing health care encounters
by individual rotavirus serotype
In the per-protocol analysis, the efficacy of RV5 in reducing
the need for hospitalisations and ED visits caused by
episodes of RVGE associated with rotavirus G-types G1,
G2, G3, G4, and G9 was also determined (Table 3). During
the 3.1 years of follow-up in REST+FES in Finland, 90.3%
of the hospitalisations and ED visits in Finland were
associated with G1 rotaviruses (18 episodes among vaccine
recipients and 383 among placebo recipients). RV5 reduced
the rate of combined hospitalisations and ED visits caused
by G1 rotaviruses by 95.3% (95% CI: 92.5–97.2%). RV5
also reduced the rate of combined hospitalisations and ED
visits resulting from G3 and G9 rotaviruses by 91.7% (95%
CI: 43.5–99.8) and 92.3% (95% CI: 48.5–99.8). Vaccine
efficacy against G4 rotaviruses was 66.8% (95% CI: <0–
94.2%), but the result was not significant. There were too
few G2 RVGE health care encounters (1 in the vaccine group
and 3 in the placebo group) to demonstrate efficacy against
G2 RVGE. In the corresponding intention-to-treat analysis,
the efficacy of RV5 in reducing the need for hospitalisations
and ED visits caused by episodes of RVGE associated with
rotavirus G-types G1, G2, G3, G4, and G9 was similar to
that of the per-protocol analysis (data not shown).
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of the child
In the per-protocol analysis, vaccine efficacy at reducing
health care encounters for RVGE was also calculated based
on the age of the child at the time of the contact rather than
time after the third dose (Table 4). The reductions in the
rate of hospitalisations and ED visits combined during the
first, second, and third years of life were 93.9% (95% CI:
89.1–96.9%), 94.4% (95% CI: 90.2–97.0%), and 85.9%
(95% CI: 51.6–97.2%), respectively. Of the cases in the
placebogroup,197(43.9%)occurredinchildren4–11months
of age, 231 (51.4%) occurred in children 12–23 months of
age, and 21 (4.7%) occurred in children 24–35 months of age
(Table 4). Of the cases in the vaccine group, 12 (42.8%) hos-
pitalisations and ED visits occurred in children 4–11 months
of age, 13 (46.4%) in children 12–23 months of age, and 3
(10.7%) in children 24–35 months of age. Figure 1 shows the
accumulation of all RVGE cases requiring hospitalisations
and ED visits, respectively, by age, in all Finnish participants
of REST, and those followed in FES. As shown in Fig. 1,i n
Finland, the majority of RVGE healthcare encounters
occurred in the first two years of life, and vaccination with
RV5 dramatically reduced the number of rotavirus-
attributable healthcare encounters.
RV5 efficacy at reducing health care encounters for AGE
of any aetiology
In an intention-to-treat analysis, during the combined
period of REST+FES, vaccine efficacy against combined
hospitalisations and ED visits for AGE was 62.4% (95%
CI: 57.6–66.6%), with a 64.8% (95% CI: 57.6–70.9%)
reduction in hospitalisations and a 60.6% (95% CI: 54.1–
66.2%) reduction in ED visits.
Intussusception
There were no cases of intussusception during the FES
period.
Discussion
FES was designed to evaluate whether the protection
observed in REST 365 days after the last dose of RV5
468 1 0 1 2 1 4 1 6 1 8 2 0 2 2 2 4 2 6 2 8 3 0 3 2 3 4
C
u
m
u
l
a
t
i
v
e
 
N
u
m
b
e
r
 
o
f
 
R
o
t
a
v
i
r
u
s
-
P
o
s
i
t
i
v
e
 
G
a
s
t
r
o
e
n
t
e
r
i
t
i
s
 
V
i
s
i
t
s
 
Age (Months)
36
Placebo -ED Visits
Placebo -Hospitalisations
RV5 -ED Visits
RV5 -Hospitalisations
0
50
100
150
200
250
300
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Table 4 Efficacy of RV5 against all RVGE health care encounters, by age of the child at time of RVGE, in the per-protocol population of
REST+FES
Age (months)
a ED visits Hospitalisations ED visits+hospitalisations
Number % Rate reduction
(95% CI)
Number % Rate reduction (95% CI) Number % Rate reduction
(95% CI)
RV5 Placebo RV5 Placebo RV5 Placebo
4–11 9 113 92.0 (84.3, 96.5) 3 84 96.4 (89.2, 99.3) 12 197 93.9 (89.1, 96.9)
12–23 6 123 95.1 (89.1, 98.2) 7 108 93.5 (86.2, 97.5) 13 231 94.4 (90.2, 97.0)
24–35 0 6 100.0 (14.1, 100.0) 3 15 80.2 (28.5, 96.2) 3 21 85.9 (51.6, 97.2)
36–43
b 0 0 NA 0 0 NA 0 0 NA
Total 15 242 93.8 (89.6, 96.6) 13 207 93.7 (89.0, 96.7) 28 449 93.8 (90.8, 95.9)
Infants who received three doses of RV5 or placebo; follow-up started 14 days after dose 3
CI confidence interval, ED emergency department, FES Finnish Extension Study, NA not applicable, REST Rotavirus Efficacy and Safety Trial,
RV5 pentavalent rotavirus vaccine, RVGE rotavirus gastroenteritis
aStratification of age of the child was based on the actual birthday of each child and age was rounded down to the last full month (i.e., 11.9 months would
be presented as 11 months)
bThere were 2,454 subjects aged 36–43 months followed for 618.7 person-years
1384 Eur J Pediatr (2010) 169:1379–1386was sustained in the second and third years of life for
children in Finland. The results from FES confirm previous
findings demonstrating that hospitalisations and ED visits
for RVGE continue to be common in the second year of life
for children from Finland [17]. Here, we show that the
protection of RV5 is sustained into the second year post-
vaccination, and possibly into the third year post-
vaccination. Overall, in Finland, RV5 reduced the rate of
combined hospitalisations and ED visits due to RVGE,
regardless of the rotavirus serotype, by 93.8% (95% CI:
90.8–95.9%) for up to 3.1 years after the last vaccine dose.
The results were consistent from year to year and between
studies, regardless of whether the analysis was based on the
per-protocol population or the intention-to-treat population.
The results in year 2 are consistent with year 1, and clearly
show that protection does not wane during this period,
when the disease burden is greatest. The results of FES are
very encouraging and confirm the high level of protection
observed in the Finnish cohort of REST, shown here, and
the large-scale safety study of REST, the results of which
have been published previously [15]. In other regions of the
world, the monovalent G1P1A[8] vaccine, RV1, has also
shown high efficacy against hospital admissions in children
followed for up to 2 years of age in Latin America [5] and
Asia [9]. In a cohort of 15,183 infants from ten Latin
American countries, RV1 reduced hospital admissions by
83.0% (95% CI: 73.1–89.7%) in children up to 2 years of
age [5]. In a cohort of 10,708 infants from three Asian
countries, RV1 reduced hospital admissions by 93.8% (95%
CI: 80.6–98.8%) in children followed up to 2 years of
age [9].
In REST+FES in Finland, vaccine efficacy at reducing
the rate of combined hospitalisations and ED visits was
93.9% in children <12 months of age and 94.4% in children
12–23 months of age. Therefore, no reduction in vaccine
efficacy against hospitalisations and ED visits combined,
indicators of severe RVGE, was seen up to the age of
24 months. In the third year of life, the point estimate for
the combined end point was 85.9%, but the CI was wide.
Definitive conclusions regarding vaccine efficacy beyond
24 months of age cannot be drawn from these results, but
one could speculate that the relatively few RVGE-related
hospitalisations and ED visits, or decreased relative attack
rate in the third year of life was probably due to naturally
acquired immunity [18].
RV5 also significantly reduced all AGE-related health
care encounters. In the Finnish cohort of REST, RV5
reduced hospitalisations for episodes of AGE of any
aetiology by 58.6% (95% CI: 48.2–66.9%) (data not
shown), which is comparable to the original REST study
(58.9%; 95% CI: 51.7–65.0%) [15]. This is not surprising,
considering that the majority of cases of AGE in REST
were collected in Finland. During the 3.1 years of follow-up
time in REST+FES, RV5 reduced AGE hospitalisations and
ED visits combined by 62.4% (95% CI: 57.6–66.6%).
Taken together, the results show that, over 3.1 years of
follow-up time, RV5 markedly decreased the use of health
care resources for RVGE and any AGE among Finnish
infants. In the United States, RV5 has been highly effective
postlicensure [20]. RV5 reduced hospitalizations and ED
visits for RVGE by 100% and AGE by 59% over the course
of two rotavirus seasons. Furthermore, RV5 was associated
with a 66% reduction in the number of AGE-related
hospitalisations and ED visit days, and a 74% reduction
in related costs.
Analysis by individual rotavirus G-type indicated that
vaccination with RV5 provided a high level of sustained
protection against RVGE due to genotypes G1, G3, and G9.
G2 was rare in Finland at the time of REST and FES, and
t h e r ew e r et o of e wh e a l t hc a r ee n c o u n t e r st os h o w
significant protection against G2 RVGE. After the comple-
tion of FES, G2 rotaviruses have become more common in
Finland [14]. Recent reports have shown that infants
vaccinated with the monovalent G1P1A [8] vaccine, RV1,
are susceptible to outbreaks with other genotypes [2, 7]. As
for RV5, it is not known whether the efficacy against G2
RVGE will be greater than that provided by RV1.
Regarding G4, there were only 12 G4-related hospital-
isations and ED visits, too few to demonstrate significant
efficacy, but it would be reasonable to assume that Finnish
infants would be afforded a high level of protection against
G4 rotavirus-related hospitalisations and ED visits similar
to that demonstrated in the original REST study [12, 15].
In conclusion, the results from FES show that, in
Finland, RV5 vaccination provides a high level of protec-
tion from RVGE through the second year and probably in
the third year of life. These results support the decision by
the Finnish government to introduce routine rotavirus
vaccination with RV5 into the national immunisation
schedule [6], and provide an estimate of the benefits
expected to be seen as a result of the universal mass
vaccination with RV5. Continued postlicensure surveillance
will determine whether the benefits of universal rotavirus
vaccination in Finland will correspond to the findings of
REST+FES shown here.
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